United States· US:79378-230_560d193b-5be5-4799-adfc-f7b36dddd434
Livmarli
A medicinal product containing maralixibat chloride, registered in United States by Mirum Pharmaceuticals Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- MARALIXIBAT CHLORIDE
- Manufacturer
- Mirum Pharmaceuticals Inc.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1179378230301 BOTTLE in 1 CARTON (79378-230-30) / 30 TABLET in 1 BOTTLE
- ndc1179378-230-30
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Maralixibat chloride in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLIVMARLIMirum Pharmaceuticals International B.V., Amsterdam
- SpainLIVMARLI 30 MG COMPRIMIDOSMirum Pharmaceuticals International B.V.
- FinlandLivmarliMirum Pharmaceuticals International B.V.
- United KingdomLivmarli 30mg tabletsMirum Pharmaceuticals International BV
- IrelandLivmarli 30 mg tabletsMirum Pharmaceuticals International B.V.
- IcelandLivmarliMirum Pharmaceuticals International B.V.
- SwedenLivmarli 30 mg TablettMirum Pharmaceuticals International B.V.
- BelgiumLivmarli 10 mgMirum Pharmaceuticals International
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Livmarli
- Liechtenstein · Livmarli
- Norway · Livmarli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c49d060e-3e64-4baf-a84d-db2fcffc8c15 GET /v1/drugs/c49d060e-3e64-4baf-a84d-db2fcffc8c15?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "30",
"substance": "MARALIXIBAT CHLORIDE",
"productndc": "79378-230",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA219485",
"marketing_category": "NDA"
}See everything about maralixibat chloride.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.